Form 4: Decheng Capital Reduces Stake in BeyondSpring Inc.

Decheng Capital, a 10% owner and director-affiliated entity, reported sales of BeyondSpring Inc. ordinary shares in early September 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and entity affiliated with a director, sold a total of 8,999 ordinary shares of BeyondSpring Inc. across three transactions.
• The sales occurred on September 4, 2025, September 5, 2025, and September 8, 2025.
• These transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled sales.
• On September 4, 2025, 803 shares were sold at a weighted average price of $1.82 per share, with prices ranging from $1.79 to $1.88.
• On September 5, 2025, 1,106 shares were sold at a weighted average price of $1.86 per share, with prices ranging from $1.82 to $1.90.
• On September 8, 2025, 7,090 shares were sold at a weighted average price of $1.93 per share, with prices ranging from $1.79 to $1.99.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,895,756 ordinary shares directly.
• Other affiliated entities, Decheng Capital China Life Sciences USD Fund II, L.P. and Decheng Capital Global Healthcare Fund (Master), LP, indirectly hold 1,617,409 and 891,734 ordinary shares, respectively.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to insider selling by a significant shareholder and director-affiliated entity. While the sales are part of a 10b5-1 plan, which mitigates the immediate negative perception, a reduction in insider stake is generally viewed unfavorably.

Positives

• The reported sales were made pursuant to a Rule 10b5-1(c) plan, which indicates pre-scheduled, non-discretionary transactions, potentially mitigating the perception of opportunistic insider selling.

Negatives

• A significant shareholder and director-affiliated entity is reducing its stake in the company, which could be interpreted by the market as a lack of conviction in the company's future prospects or a strategic reallocation of capital.

Risks

• Potential negative market perception and downward pressure on share price due to insider selling by a 10% owner and director-affiliated entity.
• Reduced alignment of interests between a major institutional investor and other shareholders as its stake decreases.

Future Outlook

No specific future outlook or guidance for BeyondSpring Inc. is provided in this insider transaction report.

Management Comments

• Dr. Xiangmin Cui, as manager of the general partners for the Decheng Capital funds, disclaims beneficial ownership of the securities held by the funds, except to the extent of his proportionate pecuniary interest therein.

Industry Context

This Form 4 filing reports specific insider transactions and does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The reported sales of ordinary shares by Decheng Capital China Life Sciences USD Fund III, L.P. are considered related party transactions, as Decheng Capital is a 10% owner and affiliated with a director of BeyondSpring Inc.

Stakeholder Impact

• Shareholders may interpret the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• The reduction in stake by a major institutional investor could alter the ownership structure and influence on corporate governance.

Next Steps

• The Reporting Person undertakes to provide the Issuer, any security holder, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the reported ranges.

Key Dates

Recommendation

While insider selling by a significant shareholder is typically a negative indicator, the sales are part of a pre-planned 10b5-1 program, which suggests a systematic approach rather than a reactive move based on immediate negative news. The total number of shares sold is relatively small compared to the overall holdings of Decheng Capital's affiliated funds. Investors should monitor future insider activity and company performance, but a 'hold' recommendation is appropriate given the pre-planned nature of the sales and the absence of other significant negative disclosures in this specific filing.

Keywords

BeyondSpring, BYSI, Decheng Capital, insider selling, Form 4, beneficial ownership, equity sales, 10b5-1 plan